LONDON, December 9, 2022 (ITIA Press Release)
The International Tennis Integrity Agency (ITIA) confirms that Kamil Majchrzak, a 26-year-old Polish tennis player, has been provisionally suspended under Article 7.12.1 of the 2022 Tennis Anti-Doping Programme (TADP)The ITIA sent the player a pre-Charge Notice of an Anti-Doping Rule Violation on 30 November 2022 under Article 2.1 of the Programme (presence of a Prohibited Substance in a Player’s Sample) and/or Article 2.2 (Use of a Prohibited Substance without a valid TUE).
Majchrzak, who had an ATP ranking of 78 at the time of being tested, provided samples whilst competing at three events – the Sofia Open in September, Japan Open in October and the FILA Open Seoul Challenger in October. The samples from each of these tests were split into A and B samples and the subsequent analysis of the A samples found that:
- One sample contained SARM S-22 and a metabolite of LGD-4033
- Two samples contained SARM S-22 and metabolites of a PPARδ agonist
SARM S-22, LGD-4033 and PPARδ agonists are all non-Specified substances listed in the 2022 World Anti-Doping Agency (WADA) Prohibited List. Adverse Analytical Findings for non-Specified Substances carry a mandatory provisional suspension.
The player has the right to request that the B samples are analysed to see if they confirm the A sample findings. While provisionally suspended, he is ineligible to compete in or attend any sanctioned tennis events organised by the governing bodies of the sport.
